These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 32673844)

  • 21. Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancer.
    Swami U; Agarwal N
    Cancer Treat Res Commun; 2020; 25():100205. PubMed ID: 32822968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States.
    Hussain A; Jiang S; Varghese D; Appukkuttan S; Kebede N; Gnanasakthy K; Macahilig C; Waldeck R; Corman S
    BMC Cancer; 2022 Mar; 22(1):304. PubMed ID: 35317768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study.
    Hegele A; Häußermann R; Schultheis S; Skrobek L; Vink M; Hollwegs S; Ludwig M; Huwe P; Maywurm M; Bartsch-Polle A; Weber J; Thiemer M; Varughese D
    J Cancer Res Clin Oncol; 2024 Sep; 150(9):414. PubMed ID: 39249593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China.
    Ming J; Wu Y; Han R; Xu X; Waldeck R; Hu S
    Adv Ther; 2023 Mar; 40(3):1087-1103. PubMed ID: 36630046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide.
    Wallis CJD; Chandrasekar T; Goldberg H; Klotz L; Fleshner N; Satkunasivam R; Klaassen Z
    Eur Urol Oncol; 2018 Aug; 1(3):238-241. PubMed ID: 31102627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer.
    Mori K; Kimura T; Fukuokaya W; Iwatani K; Sakanaka K; Kurokawa G; Yanagisawa T; Sasaki H; Miki J; Shimomura T; Miki K; Hatano T; Endo K; Egawa S
    Int J Clin Oncol; 2020 Mar; 25(3):479-485. PubMed ID: 31512007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Darolutamide (Nubeqa) for prostate cancer.
    Med Lett Drugs Ther; 2019 Dec; 61(1587):201-202. PubMed ID: 31999669
    [No Abstract]   [Full Text] [Related]  

  • 28. [Darolutamide: A new drug for non-metastatic castration-resistant prostate cancer].
    Zhang F; Lu YP
    Zhonghua Nan Ke Xue; 2020 Apr; 26(4):364-368. PubMed ID: 33351306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Managing Nonmetastatic Castration-resistant Prostate Cancer.
    Mateo J; Fizazi K; Gillessen S; Heidenreich A; Perez-Lopez R; Oyen WJG; Shore N; Smith M; Sweeney C; Tombal B; Tomlins SA; de Bono JS
    Eur Urol; 2019 Feb; 75(2):285-293. PubMed ID: 30119985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The development of apalutamide for the treatment of prostate cancer.
    Isaacsson Velho P; Tofani Sant' Anna P; Pereira da Silva RF; Dal Ponte Ferreira R; Venero FC
    Expert Opin Drug Discov; 2021 Mar; 16(3):217-226. PubMed ID: 33003959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
    Chi KN; Chowdhury S; Bjartell A; Chung BH; Pereira de Santana Gomes AJ; Given R; Juárez A; Merseburger AS; Özgüroğlu M; Uemura H; Ye D; Brookman-May S; Mundle SD; McCarthy SA; Larsen JS; Sun W; Bevans KB; Zhang K; Bandyopadhyay N; Agarwal N
    J Clin Oncol; 2021 Jul; 39(20):2294-2303. PubMed ID: 33914595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives.
    Berruti A; Bracarda S; Caffo O; Cortesi E; D'Angelillo R; Del Re M; Facchini G; Pappagallo G; Procopio G; Sabbatini R; Santini D
    Cancer Treat Rev; 2023 Apr; 115():102525. PubMed ID: 36822009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial.
    Smith MR; Shore N; Tammela TL; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Kuss I; Le Berre MA; Mohamed AF; Odom D; Bartsch J; Snapir A; Sarapohja T; Fizazi K
    Eur J Cancer; 2021 Sep; 154():138-146. PubMed ID: 34273811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.
    Kumar J; Jazayeri SB; Gautam S; Norez D; Alam MU; Tanneru K; Bazargani S; Costa J; Bandyk M; Ganapathi HP; Koochekpour S; Balaji KC
    Urol Oncol; 2020 Nov; 38(11):826-834. PubMed ID: 32605736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of enzalutamide and apalutamide in the treatment of non-metastasic castration-resistant prostate cancer: Indirect comparison.
    Nieto-Gómez P; Ubago-Pérez R; Cabeza-Barrera J
    Actas Urol Esp (Engl Ed); 2019 Sep; 43(7):355-363. PubMed ID: 31133348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Darolutamide (ODM-201) for the treatment of prostate cancer.
    Shore ND
    Expert Opin Pharmacother; 2017 Jun; 18(9):945-952. PubMed ID: 28490267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apalutamide for the treatment of metastatic castration-sensitive prostate cancer.
    Dror CM; Chi KN
    Future Oncol; 2020 Dec; 16(35):2905-2916. PubMed ID: 32885994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical Trial.
    Roy S; Malone S; Wing K; Chowdhury S; Kishan AU; Sun Y; Wallis CJD; Mohamad O; Jia AY; Swami U; Zaorsky NG; Morgan SC; Ong M; Agarwal N; Spratt DE; Small EJ; Saad F
    JAMA Netw Open; 2024 Oct; 7(10):e2439434. PubMed ID: 39405060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer.
    Feng FY; Thomas S; Saad F; Gormley M; Yu MK; Ricci DS; Rooney B; Brookman-May S; McCarthy S; Olmos D; Chowdhury S; Hadaschik B; Liu Y; Davicioni E; Smith MR; Small EJ
    JAMA Oncol; 2021 Jul; 7(7):1005-1014. PubMed ID: 34081076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review.
    Cattrini C; Caffo O; De Giorgi U; Mennitto A; Gennari A; Olmos D; Castro E
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.